The prevalence of chronic kidney disease is rising globally, with millions of individuals affected. Factors such as renal illnesses, diabetes, and hypertension contribute to the growing incidence, ...
This trial demonstrated that Ozempic®, a GLP-1 receptor agonist, significantly reduces the risk of progression in chronic kidney disease and cardiovascular mortality in patients with type 2 diabetes.